Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study
Authors
Keywords
Pancreatic ductal adenocarcinoma (PDAC), Carbohydrate antigen 19-9 (CA19-9), Prognosis, Overall survival (OS)
Journal
World Journal of Surgical Oncology
Volume 12, Issue 1, Pages 171
Publisher
Springer Nature
Online
2014-06-03
DOI
10.1186/1477-7819-12-171
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gemcitabine-Based Chemoradiotherapy Followed by Surgery for Borderline Resectable and Locally Unresectable Pancreatic Ductal Adenocarcinoma
- (2014) Motoyuki Kobayashi et al. PANCREAS
- The Incidence and Survival Rate of Population-Based Pancreatic Cancer Patients: Shanghai Cancer Registry 2004–2009
- (2013) Jianfeng Luo et al. PLoS One
- Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study
- (2013) Marius Distler et al. International Journal of Surgery
- CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
- (2012) Werner Hartwig et al. ANNALS OF SURGICAL ONCOLOGY
- AB0 blood group and prognosis in patients with pancreatic cancer
- (2012) Nuh N Rahbari et al. BMC CANCER
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma
- (2012) Teiichi Sugiura et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Pancreatic Cancer Surgery in the New Millennium
- (2011) Werner Hartwig et al. ANNALS OF SURGERY
- HER3 Overexpression as an Independent Indicator of Poor Prognosis for Patients with Curatively Resected Pancreatic Cancer
- (2011) Toshiki Hirakawa et al. ONCOLOGY
- Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer
- (2010) Naru Kondo et al. ANNALS OF SURGICAL ONCOLOGY
- Resectable Pancreatic Cancer: Who Really Benefits From Resection?
- (2009) Giuliano Barugola et al. ANNALS OF SURGICAL ONCOLOGY
- Preoperative Serum CA19-9 and Dissected Peripancreatic Tissue Margin as Determiners of Long-Term Survival in Pancreatic Cancer
- (2009) Mina Waraya et al. ANNALS OF SURGICAL ONCOLOGY
- Margin Clearance and Outcome in Resected Pancreatic Cancer
- (2009) David K. Chang et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma
- (2009) Joshua G. Barton et al. JOURNAL OF GASTROINTESTINAL SURGERY
- The Impact of Resection Margin Status and Postoperative CA19-9 Levels on Survival and Patterns of Recurrence After Postoperative High-Dose Radiotherapy With 5-FU—Based Concurrent Chemotherapy for Resectable Pancreatic Cancer
- (2008) Timothy J. Kinsella et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704
- (2008) Adam C. Berger et al. JOURNAL OF CLINICAL ONCOLOGY
- New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer
- (2008) Rahul Pannala et al. LANCET ONCOLOGY
- Prognostic Factors After Resection of Pancreatic Cancer
- (2008) Michio Ueda et al. WORLD JOURNAL OF SURGERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now